ClinicalTrials.gg
CompletedNCT05032833Updated Oct 12, 2022

Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects

A Phase 1 interventional study of 5-MeO-DMT and Placebo in Pharmacokinetics in Healthy Adults, sponsored by Beckley Psytech Limited. Completed at 1 site in United Kingdom. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-12.

Sponsored by Beckley Psytech Limited (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
25 Years to 55 Years
Sex
All
01

Study summary

The study will evaluate safety, tolerability and PK profile of 5-MeO-DMT in healthy subjects

02

Conditions studied

  • Pharmacokinetics in Healthy Adults
03

In context

Lead sponsor

Beckley Psytech Limited is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

First submitted before Beckley Psytech Limited became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

* Medically healthy based on medical records and study specific assessments

Exclusion criteria

Exclusion Criteria:

* Presence or history of severe adverse reaction to any drug or drug

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    5-MeO-DMT arm

    Drug: 5-MeO-DMT

  • Placebo comparator
    Placebo arm

    Other: Placebo

Interventions

  • A single dose of 5-MeO-DMT will be administered intranasally

  • OtherPlacebo

    A single dose of placebo will be administered intranasally

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with treatment emergent AEs (TEAES)

    Time frame: From screening through to the follow up visit, up to 65 days

Secondary outcomes

  1. Peak plasma concentration (Cmax)

    Time frame: Day 1 (dosing day) and Day 2

  2. Time to reach Cmax (tmax)

    Time frame: Day 1 (dosing day) and Day 2

  3. Area under the plasma concentration- time curve

    Time frame: Day 1 (dosing day) and Day 2

07

Study locations

1 site
  • King's College London
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Due to the UK GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Jul 2022, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2021
First posted
Sep 2, 2021
StartActual
Sep 22, 2021
Primary completionActual
Jul 7, 2022
CompletionActual
Jul 7, 2022
Last update
Oct 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05032833
Responsible party
Sponsor
First posted
Sep 2, 2021
Start date
Sep 22, 2021
Primary completion
Jul 7, 2022
Completion
Jul 7, 2022
Last update
Oct 12, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxydimethyltryptamines

Start the discussion